Drug name - Invega Sustenna
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(8 years from now) | |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Treatment: Treatment of schizophrenia; treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loading doses of paliperidone palmitate followed by maintenance dose(s); dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 39MG/0.25ML (39MG/0.25ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 78MG/0.5ML (78MG/0.5ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 117MG/0.75ML (117MG/0.75ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 156MG/ML (156MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 234MG/1.5ML (156MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.